retatrutide nejm 2023 obesity trial ly3437943 Retatrutide: Phase 3 Results (Up to 28.7% Weight Loss), Mechanism, Trials & 2026 Updates Retatrutide for Obesity: Phase 2
Description
Products like Ozempic, Mounjaro, and Zepbound are FDA-regulated injectables
Based on their findings, they will create a personalized nutrition plan tailored to support you in achieving your desired outcomes
Role of GLP-1 in obesity GLP-1 reduces appetite and food intake through its actions in the CNS
The FDA's enforcement action targeted platforms making claims implying compounded products are equivalent to FDA-approved drugs, making unsubstantiated safety and efficacy claims, or obscuring which entity compounds the medication
Pham TK, et al
